New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
08:50 EDTKERXKeryx announces submission of MAA for Zerenex to EMA
Keryx Biopharmaceuticals announced it has submitted a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, seeking the approval of Zerenex as a treatment for hyperphosphatemia in patients with chronic kidney disease, or CKD, including dialysis- and non-dialysis dependent CKD. The MAA will be reviewed by the EMA Committee for Medicinal Products for Human Use and the review will be conducted under the Centralized Authorization Procedure. An approval under the Centralized Authorization Procedure provides one marketing authorization which is valid in all 27 member states of the European Union, as well as in Norway, Liechtenstein and Iceland.
News For KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
11:10 EDTKERXKeryx management to meet with Oppenheimer
Subscribe for More Information
October 17, 2014
14:41 EDTKERXKeryx down 4.4% to $15.31, Orange Book cited
Shares of Keryx are lower in afternoon trading after no NCE decision in the Orange Book was updated today, as pointed out by TheStreet's Adam Feuerstein earlier on Twitter.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use